Clinically relevant quality assurance (QA) for prostate RapidArc plans: Gamma maps and DVH-based evaluation

M. Cozzolino, C. Oliviero, G. Califano, S. Clemente, P. Pedicini, R. Caivano, C. Chiumento, A. Fiorentino, V. Fusco

Research output: Contribution to journalArticle

Abstract

The aim of this paper is to evaluate clinically relevant quality assurance (QA) tests for RapidArc prostate patients. 26 plans were verified by the COMPASS system that provides an independent angle response and a reconstruction of dose distribution in patient CT model. Plan data were imported from treatment planning system via DICOM. The fluencies, measured by a 2D detector, were used by COMPASS to forward calculate dose in CT patients and reconstruct dose-volume-histogram (DVH). The gamma analysis was performed, using both the criteria 3%-3-mm and 2%-2mm, for the whole grid patient and the per-structure volume. A DVH-based analysis was accomplished for target and organs-at-risk (OAR). The correlation between gamma passing rates and DVH discrepancies was performed using Pearson's test. Sensitivity, specificity and accuracy of whole and per-structure gamma method were calculated.No significant DVH deviation was observed for target and OAR. Weak correlation between gamma passing rates and dosimetric deviations was observed, all significant r-values were negative. The whole gamma method shows lack of sensitivity to detect dosimetric deviations >5%. Instead, a better balance between sensitivity and specificity was obtained employing per structure gamma both with 3%-3mm and 2%-2mm criteria.Because of the poor correlation between DVH goals and gamma passing rates, we encourage the DVH-based gamma passing rates, when it is possible. At least, a gamma method specific for structure was strongly suggested.

Original languageEnglish
Pages (from-to)462-472
Number of pages11
JournalPhysica Medica
Volume30
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

assurance
histograms
Prostate
Organs at Risk
dosage
evaluation
COMPASS (programming language)
Sensitivity and Specificity
deviation
organs
sensitivity
planning
grids
detectors
Therapeutics

Keywords

  • 3D gamma
  • 3D quality assurance
  • COMPASS system
  • RapidArc prostate

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Physics and Astronomy(all)
  • Medicine(all)

Cite this

Clinically relevant quality assurance (QA) for prostate RapidArc plans : Gamma maps and DVH-based evaluation. / Cozzolino, M.; Oliviero, C.; Califano, G.; Clemente, S.; Pedicini, P.; Caivano, R.; Chiumento, C.; Fiorentino, A.; Fusco, V.

In: Physica Medica, Vol. 30, No. 4, 2014, p. 462-472.

Research output: Contribution to journalArticle

Cozzolino, M, Oliviero, C, Califano, G, Clemente, S, Pedicini, P, Caivano, R, Chiumento, C, Fiorentino, A & Fusco, V 2014, 'Clinically relevant quality assurance (QA) for prostate RapidArc plans: Gamma maps and DVH-based evaluation', Physica Medica, vol. 30, no. 4, pp. 462-472. https://doi.org/10.1016/j.ejmp.2014.01.003
Cozzolino, M. ; Oliviero, C. ; Califano, G. ; Clemente, S. ; Pedicini, P. ; Caivano, R. ; Chiumento, C. ; Fiorentino, A. ; Fusco, V. / Clinically relevant quality assurance (QA) for prostate RapidArc plans : Gamma maps and DVH-based evaluation. In: Physica Medica. 2014 ; Vol. 30, No. 4. pp. 462-472.
@article{e4bbb505313d41f093149e1e11e76afa,
title = "Clinically relevant quality assurance (QA) for prostate RapidArc plans: Gamma maps and DVH-based evaluation",
abstract = "The aim of this paper is to evaluate clinically relevant quality assurance (QA) tests for RapidArc prostate patients. 26 plans were verified by the COMPASS system that provides an independent angle response and a reconstruction of dose distribution in patient CT model. Plan data were imported from treatment planning system via DICOM. The fluencies, measured by a 2D detector, were used by COMPASS to forward calculate dose in CT patients and reconstruct dose-volume-histogram (DVH). The gamma analysis was performed, using both the criteria 3{\%}-3-mm and 2{\%}-2mm, for the whole grid patient and the per-structure volume. A DVH-based analysis was accomplished for target and organs-at-risk (OAR). The correlation between gamma passing rates and DVH discrepancies was performed using Pearson's test. Sensitivity, specificity and accuracy of whole and per-structure gamma method were calculated.No significant DVH deviation was observed for target and OAR. Weak correlation between gamma passing rates and dosimetric deviations was observed, all significant r-values were negative. The whole gamma method shows lack of sensitivity to detect dosimetric deviations >5{\%}. Instead, a better balance between sensitivity and specificity was obtained employing per structure gamma both with 3{\%}-3mm and 2{\%}-2mm criteria.Because of the poor correlation between DVH goals and gamma passing rates, we encourage the DVH-based gamma passing rates, when it is possible. At least, a gamma method specific for structure was strongly suggested.",
keywords = "3D gamma, 3D quality assurance, COMPASS system, RapidArc prostate",
author = "M. Cozzolino and C. Oliviero and G. Califano and S. Clemente and P. Pedicini and R. Caivano and C. Chiumento and A. Fiorentino and V. Fusco",
year = "2014",
doi = "10.1016/j.ejmp.2014.01.003",
language = "English",
volume = "30",
pages = "462--472",
journal = "Physica Medica",
issn = "1120-1797",
publisher = "Associazione Italiana di Fisica Medica",
number = "4",

}

TY - JOUR

T1 - Clinically relevant quality assurance (QA) for prostate RapidArc plans

T2 - Gamma maps and DVH-based evaluation

AU - Cozzolino, M.

AU - Oliviero, C.

AU - Califano, G.

AU - Clemente, S.

AU - Pedicini, P.

AU - Caivano, R.

AU - Chiumento, C.

AU - Fiorentino, A.

AU - Fusco, V.

PY - 2014

Y1 - 2014

N2 - The aim of this paper is to evaluate clinically relevant quality assurance (QA) tests for RapidArc prostate patients. 26 plans were verified by the COMPASS system that provides an independent angle response and a reconstruction of dose distribution in patient CT model. Plan data were imported from treatment planning system via DICOM. The fluencies, measured by a 2D detector, were used by COMPASS to forward calculate dose in CT patients and reconstruct dose-volume-histogram (DVH). The gamma analysis was performed, using both the criteria 3%-3-mm and 2%-2mm, for the whole grid patient and the per-structure volume. A DVH-based analysis was accomplished for target and organs-at-risk (OAR). The correlation between gamma passing rates and DVH discrepancies was performed using Pearson's test. Sensitivity, specificity and accuracy of whole and per-structure gamma method were calculated.No significant DVH deviation was observed for target and OAR. Weak correlation between gamma passing rates and dosimetric deviations was observed, all significant r-values were negative. The whole gamma method shows lack of sensitivity to detect dosimetric deviations >5%. Instead, a better balance between sensitivity and specificity was obtained employing per structure gamma both with 3%-3mm and 2%-2mm criteria.Because of the poor correlation between DVH goals and gamma passing rates, we encourage the DVH-based gamma passing rates, when it is possible. At least, a gamma method specific for structure was strongly suggested.

AB - The aim of this paper is to evaluate clinically relevant quality assurance (QA) tests for RapidArc prostate patients. 26 plans were verified by the COMPASS system that provides an independent angle response and a reconstruction of dose distribution in patient CT model. Plan data were imported from treatment planning system via DICOM. The fluencies, measured by a 2D detector, were used by COMPASS to forward calculate dose in CT patients and reconstruct dose-volume-histogram (DVH). The gamma analysis was performed, using both the criteria 3%-3-mm and 2%-2mm, for the whole grid patient and the per-structure volume. A DVH-based analysis was accomplished for target and organs-at-risk (OAR). The correlation between gamma passing rates and DVH discrepancies was performed using Pearson's test. Sensitivity, specificity and accuracy of whole and per-structure gamma method were calculated.No significant DVH deviation was observed for target and OAR. Weak correlation between gamma passing rates and dosimetric deviations was observed, all significant r-values were negative. The whole gamma method shows lack of sensitivity to detect dosimetric deviations >5%. Instead, a better balance between sensitivity and specificity was obtained employing per structure gamma both with 3%-3mm and 2%-2mm criteria.Because of the poor correlation between DVH goals and gamma passing rates, we encourage the DVH-based gamma passing rates, when it is possible. At least, a gamma method specific for structure was strongly suggested.

KW - 3D gamma

KW - 3D quality assurance

KW - COMPASS system

KW - RapidArc prostate

UR - http://www.scopus.com/inward/record.url?scp=84899490264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899490264&partnerID=8YFLogxK

U2 - 10.1016/j.ejmp.2014.01.003

DO - 10.1016/j.ejmp.2014.01.003

M3 - Article

C2 - 24480527

AN - SCOPUS:84899490264

VL - 30

SP - 462

EP - 472

JO - Physica Medica

JF - Physica Medica

SN - 1120-1797

IS - 4

ER -